CommercialCoverageMedium impact
11.14.06j, Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)
Independence Blue Cross·Orthopedics, Sports Medicine, General Surgery·Medical Policy
Effective date
Apr 16, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued policy 11.14.06j regarding coverage of Autologous Chondrocyte Implantation (ACI) and other cell-based treatments for focal articular cartilage lesions, effective April 16, 2025. The billing team must review the full policy text to identify any changes to coverage criteria, prior authorization requirements, or billing code updates that may affect claim submission and reimbursement for these procedures.
Action Required
By April 16, 2025: Billing team must obtain and review the complete policy text from the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-11-14-06j). Update all billing system rules, encounter forms, and provider documentation templates to reflect any changes to coverage determination, prior authorization requirements, or allowed billing codes for ACI and cell-based cartilage treatments. Communicate changes to orthopedic providers and billing staff. Note: Specific billing codes and detailed requirements are not available in the provided summary; access the full policy immediately to identify affected CPT/HCPCS codes and implement necessary system updates before the effective date.